Akhurst J S
Britannia Pharmaceuticals, Redhill, UK.
Eur Addict Res. 1999 Mar;5(1):43-9. doi: 10.1159/000018962.
Data were collected on 1,074 opiate detoxifications conducted with lofexidine, from 40 drug dependency units in the United Kingdom. 671 patients (62.5%) attempted a detoxification in the community, with the remainder attempting an inpatient detoxification. Patients completing the detoxification started on a mean dose of 0.8 mg/day (median 0.6 mg/day), titrating to a mean dose of 2.2 mg/day (median 1.6 mg/day) and detoxifying in a mean of 10 days (median 10 days). Overall 614 patients (60.4%) successfully completed the detoxification. The most frequently recorded adverse events were dry mouth (5.3%), dizziness (8.5%) and sedation (6.6%). In conclusion, lofexidine is widely and successfully used to rapidly detoxify patients from a range of opiates.
收集了英国40个药物依赖治疗单位使用洛非西定进行的1074例阿片类药物脱毒治疗的数据。671例患者(62.5%)尝试在社区进行脱毒治疗,其余患者尝试住院脱毒治疗。完成脱毒治疗的患者起始平均剂量为0.8毫克/天(中位数为0.6毫克/天),滴定至平均剂量2.2毫克/天(中位数为1.6毫克/天),平均在10天内(中位数为10天)完成脱毒。总体而言,614例患者(60.4%)成功完成脱毒治疗。最常记录的不良事件为口干(5.3%)、头晕(8.5%)和镇静(6.6%)。总之,洛非西定被广泛且成功地用于使患者快速从多种阿片类药物中脱毒。